Does Suboxone Help With Meth Addiction?

Suboxone, a combination of buprenorphine and naloxone, is not approved by the FDA for treating methamphetamine addiction and is not a standard treatment for it. Suboxone is designed and prescribed for opioid use disorder. However, a growing body of research suggests that buprenorphine, the active opioid component in Suboxone, may reduce meth cravings and drug-seeking behavior through receptor pathways that go beyond its known effects on opioid receptors. The evidence is early and comes mostly from small clinical trials and animal studies, but it has generated genuine interest among addiction researchers looking for pharmacological options in a field that has almost none.

Why Buprenorphine Might Affect Meth Use at All

The idea that an opioid medication could do anything useful for a stimulant addiction sounds counterintuitive at first. Meth works primarily on dopamine, while Suboxone targets opioid receptors. But buprenorphine is pharmacologically unusual. It does not simply activate one type of receptor. Among its many actions, it blocks the kappa opioid receptor, a receptor system involved in stress, dysphoria, and craving across multiple types of addiction. By blocking kappa receptors, buprenorphine may dampen the intense craving and negative emotional states that drive people back to meth use.¹

Animal research has added another piece to this puzzle. In rat models, buprenorphine reduced both meth self-administration and the motivation to seek meth, and it did so by activating a receptor called the nociceptin/orphanin FQ peptide receptor (NOP receptor). Researchers found that buprenorphine cut drug-seeking behavior triggered by environmental context and by re-exposure to meth itself, though it did not block cue-triggered seeking.² That distinction matters: it suggests buprenorphine may help people resist relapse in some situations (being in places associated with past use, encountering the drug itself) but not in others (seeing paraphernalia or other conditioned cues).

Meanwhile, research into the kappa opioid system in the brain has shown that meth exposure itself alters kappa receptor activity in regions associated with decision-making and craving. After repeated meth use in animal models, kappa receptor gene expression increased during withdrawal, suggesting the brain’s stress-craving circuitry ramps up as someone tries to stay clean.³ If buprenorphine can counteract that upregulation by blocking kappa receptors, it could theoretically ease the withdrawal-driven craving that makes early abstinence from meth so difficult.

What Human Trials Actually Show

A handful of clinical trials have tested buprenorphine specifically for meth craving and use, and the results lean positive but come with serious caveats about study size and design.

In one randomized, placebo-controlled trial, participants undergoing a behavioral treatment program (the Matrix model) received either buprenorphine or placebo as an add-on. Craving scores were significantly lower in the buprenorphine group across most measurement points, and the proportion of positive drug tests was also significantly lower at most time points compared to placebo.⁴ This trial framed buprenorphine as an adjunct to behavioral therapy rather than a standalone medication, which is an important distinction. Nobody is suggesting you can take Suboxone alone and stop using meth.

Another randomized trial compared buprenorphine head-to-head with bupropion (an antidepressant sometimes used for stimulant cravings). Both medications reduced meth craving, but buprenorphine at 8 mg per day outperformed bupropion significantly. The study authors noted, however, that craving tends to decline over time even without medication, so the relevant finding is not that both drugs worked but that buprenorphine worked better than bupropion.⁵

These are encouraging signals, but both trials were relatively small and conducted in single centers. No large, multi-site randomized trial has yet confirmed buprenorphine as an effective treatment for meth use disorder on its own. The evidence is at the “promising early-stage” level, not the “change of clinical practice” level.

The Polysubstance Reality

In practice, the question of whether Suboxone helps with meth often comes up not in the abstract but in a specific, common clinical scenario: someone is being treated with buprenorphine for opioid addiction and is also using meth. This describes a large share of people in opioid treatment programs. In one study of patients receiving buprenorphine for opioid use disorder, over a third were also using meth or amphetamines at baseline.⁶

For these patients, the question is not really “does Suboxone treat my meth problem” but rather “does my meth use undermine my opioid treatment?” The answer is clearly yes. That same study found that patients using meth were significantly more likely to test positive for illicit opioids during follow-up. At 12 weeks, the risk of reported illicit opioid use was nearly four times higher among those also using meth compared to those who were not.⁶ In other words, meth use actively sabotages opioid recovery.

This creates a frustrating treatment gap. The patient needs opioid treatment, and buprenorphine is one of the best tools for that. But the co-occurring meth use makes the opioid treatment less effective, and buprenorphine is not designed to address it directly.

Meth Use and Treatment Dropout

The problem gets worse when you look at whether people stay in treatment. A scoping review that examined all available studies on the subject found a consistent pattern across every single included study: patients using meth while receiving medications for opioid use disorder were more likely to drop out of treatment. And the more frequently someone used meth, the higher their dropout risk.⁷

Interestingly, the medication type seems to matter. One study that compared buprenorphine-naloxone (Suboxone) with extended-release naltrexone found that meth use had a dramatically different effect on dropout rates depending on which medication the patient was taking. Among patients on naltrexone, those who tested positive for meth had nearly three times the risk of dropping out. But among patients on buprenorphine-naloxone, meth use did not significantly increase dropout risk at all.⁸ This suggests that buprenorphine may be the better opioid treatment choice for people who are also using meth, even if it is not being prescribed for the meth use itself. Patients stay in treatment longer, which at minimum keeps the door open for addressing the meth problem through other means.

Long-Acting Buprenorphine Injections

One of the more intriguing findings comes from a retrospective study of long-acting injectable buprenorphine, a monthly injection that removes the daily pill-taking element. In a cohort of patients receiving these injections (primarily for opioid use disorder), researchers tracked meth use over six months. Among those who had been actively using meth, 70% had reduced or stopped their meth use by the six-month mark. All participants who had used meth in the past but stopped before starting the injection remained abstinent.⁹

This is a striking result, but it requires some caution. The study was retrospective and had no control group, so you cannot separate the effect of the buprenorphine itself from the effect of being engaged in regular treatment, seeing a clinician monthly, and having a structured recovery environment. People who show up consistently for injections are a self-selected group who may be more motivated to change. Still, a 70% reduction-or-cessation rate is hard to ignore, and it has spurred interest in studying long-acting formulations more rigorously for this purpose.

What Actually Has FDA Support for Meth Addiction

Here is the uncomfortable truth about meth addiction treatment: as of now, no medication has received FDA approval for treating methamphetamine use disorder. The pharmacotherapy cupboard is remarkably bare compared to what exists for opioid or alcohol addiction.

The closest thing to a pharmacological breakthrough is the combination of naltrexone and bupropion, which was tested in a large, well-designed, multi-site trial published in the New England Journal of Medicine. The combination produced a response rate of about 14%, compared to roughly 2.5% with placebo. That 11-percentage-point difference was statistically significant and clinically meaningful for a disorder where virtually nothing else has worked in rigorous trials.¹⁰ Extended follow-up from the same trial showed that the benefit continued to grow during the treatment period, with participants on the active combination showing a 27% total increase in the probability of testing negative for meth over 12 weeks.¹¹

Even this combination, though, has not yet led to FDA approval. It is used off-label by some clinicians, and it remains the strongest pharmacological evidence available. But a 14% response rate, while real, underscores how difficult meth addiction is to treat with medication alone.

Why Behavioral Treatment Remains Central

The most robust evidence for treating meth addiction does not involve any pill or injection. Contingency management, a behavioral approach that provides tangible rewards (often small amounts of money or vouchers) for negative drug tests, is consistently identified as the most effective intervention for reducing meth use. A systematic review of the literature concluded that contingency management should be prioritized by outpatient programs treating meth use disorder.¹²

The idea of paying someone not to use drugs can feel strange to people unfamiliar with it, but the logic is straightforward. Meth provides an immediate, powerful reward. Recovery requires sustained effort with mostly delayed benefits. Contingency management bridges that gap by providing an immediate competing reward. Research consistently shows it outperforms other behavioral approaches for stimulant use disorders specifically, likely because meth so thoroughly hijacks the brain’s reward circuitry that non-reward-based counseling struggles to compete.

For people already on Suboxone for opioid addiction who are also struggling with meth, combining buprenorphine treatment with contingency management (and potentially adding naltrexone-bupropion for the meth use) represents the closest thing to a comprehensive pharmacological and behavioral strategy currently available. No single medication does the full job.

Practical Takeaways If You or Someone You Know Is in This Situation

If you are on Suboxone for opioid addiction and also using meth, the most important thing to know is that your Suboxone is still worth taking. Meth use makes opioid recovery harder, but buprenorphine-based treatment appears more resilient to co-occurring meth use than naltrexone-based alternatives when it comes to keeping you in treatment. Staying in treatment matters enormously, because treatment retention is one of the strongest predictors of long-term recovery from opioid addiction regardless of what else is going on.

If you are wondering whether to ask your doctor about Suboxone specifically for meth cravings and you do not have an opioid problem, the honest answer is that the evidence is not there yet. The clinical trials that exist are small and preliminary. No prescribing guideline recommends buprenorphine for meth use disorder alone. A clinician prescribing it off-label for this purpose would be operating at the frontier of the evidence, not within established best practices.

What you can do right now is ask about contingency management programs, which have the strongest evidence base. If you are in an area where the naltrexone-bupropion combination is prescribed off-label for meth use, that conversation is also worth having with a provider familiar with the ADAPT-2 trial data. The landscape is evolving, and clinicians who specialize in addiction medicine tend to be more aware of these emerging options than general practitioners.

Why Progress Has Been So Slow

Methamphetamine addiction has been uniquely resistant to pharmacological treatment, and this is not for lack of trying. Dozens of medications have been tested in clinical trials over the past two decades, including antidepressants, antipsychotics, ADHD medications, modafinil, and various combinations. Almost all have failed to show a meaningful benefit in rigorous studies. The reasons are partly biological: meth affects multiple neurotransmitter systems simultaneously, and its effects on dopamine are so dramatic that blocking any single receptor pathway tends not to be enough. Unlike opioid addiction, where replacement therapy (methadone, buprenorphine) can stabilize the same receptor system the drug hijacked, there is no clean substitute for what meth does to the brain.

This is part of what makes the buprenorphine findings interesting, even in their early state. The fact that buprenorphine acts on kappa opioid and NOP receptor systems rather than directly on dopamine suggests it may be working through stress and craving pathways rather than trying to mimic or block the meth high itself. That indirect approach could be why it shows any signal at all when so many direct pharmacological strategies have failed. Whether that signal holds up in larger, more rigorous trials is an open question that researchers are actively pursuing.